Support of Central Spinal Fluid Biomarker Study–ADNI

2008

Cure Alzheimer’s Fund is part of a funding consortium supporting collaborative biomarker investigation of the elevation of tau and decreased concentrations of Amyloid beta 42 in the Central Spinal Fluid as evidence of the presence of the Alzheimer’s disease pathology.

Biomarkers/Diagnostics/Studies of Risk & Resilience Foundational John Trojanowski Leslie Shaw

Cerebrospinal Fluid Neuroinflammatory Signature in Alzheimer´s Disease and Related Proteopathies

P. Murali Doraiswamy, | 2020

Sex Differences in Alzheimer’s Disease Progression: Framingham Heart Study

Andrew Yoo, | 2021

Neuronal Subtype-Specific Modeling of Alzheimer’s Disease by Direct Neuronal Reprogramming of Patient Fibroblasts

Brain Donor Project, | 2021

Targeted Recruitment of Underrepresented Americans for Brain Donation Registration

Christina Lill, Lars Bertram, | 2020

Personalized Disease Prediction for Alzheimer’s Disease Using Proteome Profiling: The EPIC4AD Study

Bradley Hyman, | 2020

Creation of a Fibroblast/iPS Cell Bank to Facilitate Peripheral/Brain Comparisons, and Allow Molecular Investigations into Molecular Mechanisms Underlying Differences in Disease Aggressiveness

Paola Bovolenta, Pilar Esteve, | 2020

SFRP1 as a Therapeutic Target and Diagnostic/Prognostic Factor in Alzheimer’s Disease

Krista L. Moulder, | 2020

Characterization of Alzheimer’s Disease Molecular Biomarker Profiles Throughout the Pathobiological Continuum